Veracyte Common Stock share price logo

Veracyte Common Stock

NASDAQ: VCYT

Mid Cap

$53.19

-0.44

(-0.82%)

as on

Veracyte Common Stock Stock Performance

as on June 23, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $52.36
    $54.72
    downward going graph

    1.56%

    Downside

    2.88%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $22.61
    $54.72
    downward going graph

    57.49%

    Downside

    2.88%

    Upside

    downward going graph

Veracyte Common Stock share price movements today

Previous Close
$53.63
Open
$53.72
Volume
646.1K
Day's Low - High
$52.36 - $54.72
52 Week Low - High
$22.61 - $54.72

Veracyte Common Stock Historical Returns

1 Month Return
+ 18.12 %
3 Month Return
+ 58.59 %
1 Year Return
+ 99.14 %
3 Year Return
+ 108.34 %
5 Year Return
+ 36.11 %

Veracyte Common Stock Stock Fundamentals & Key Indicators

Check Veracyte Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.3B

EPS (TTM)

1.821

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

2.89%

PE Ratio (TTM)

49.66

Industry PE ratio

11.967777777777778

PEG Ratio

0

EBITDA

104.2M

Revenue (TTM)

541.7M

Profit Margin

16.25%

Return On Equity TTM

6.93%

Veracyte Common Stock Stock Valuation

Track how Veracyte Common Stock P/E has moved over time to understand its valuation trends.

Veracyte Common Stock in the last 5 years

  • Overview

  • Trends

Lowest (-60.60x)

June 30, 2023

Industry (11.97x)

June 23, 2026

Today (49.66x)

June 23, 2026

Highest (100.47x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 49.66x

Veracyte Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Veracyte Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$4.3B36.11%49.6616.25%NA
BUY$44.3B-11.39%41.3324.63%NA
BUY$35.9B-14.09%25.5119.55%0.8099999999999999%
BUY$172.7B-6.07%25.5115.15%0.38%
BUY$125.4B-33.67%34.3414.89%0.77%

Stock Returns calculator for Veracyte Common Stock Stock including INR - Dollar returns

The Veracyte Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Veracyte Common Stock investment value today

Current value as on today

₹2,17,769

Returns

₹1,17,769

(+117.77%)

Returns from Veracyte Common Stock Stock

₹99,139 (+99.14%)

Dollar Impact

₹18,630 (+18.63%)

Analyst Recommendation on Veracyte Common Stock Stock

Based on 15 analysts

BUY

73.33%

Buy

20.00%

Hold

6.67%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for Veracyte Common Stock. Average target price of $49.1

Veracyte Common Stock Share Price Target

Get share price movements and forecasts by analysts on Veracyte Common Stock.

What analysts predicted

-8.33%DOWNSIDE

Target Price

$49.1

Current Price

$53.19

Analyzed by

15 Analysts

Target

$49.10

Veracyte Common Stock target price $49.1, a slight downside of -8.33% compared to current price of $53.19. According to 15 analysts rating.

Indian Investors' Interest in Veracyte Common Stock Stock

Search interest for Veracyte Common Stock Stock has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-3% versus previous 30 day period

Veracyte Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
98
96
114
115
118
114
130
131
140
139
Gross Profit
68
62
77
79
78
79
89
91
104
100
Operating Income
-35
-4
4
12
4
2
-5
22
25
23
EBITDA
-24
1
13
22
9
6
6
24
45
35
Interest Expense
0
-
0
0
-
-
-
-
-
-
Depreciation
6
5
5
5
6
5
5
5
5
5
Income Before Tax
-30
-1
7
16
3
7
1
18
40
29
Income Tax Expense
-2
0
1
1
-1
0
2
0
0
1
Net Income
-28
-1
5
15
5
7
0
19
41
28
Net Profit Margin
-28.81%
-1.92%
5.01%
13.08%
4.31%
6.16%
-0.75%
14.51%
29.26%
20.64%

Veracyte Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
65
71
92
120
117
219
296
361
445
517
Gross Profit
39
43
58
83
76
145
194
248
298
360
Operating Income
-28
-26
-22
-15
-35
-81
-41
-85
16
74
EBITDA
-25
-23
-17
-7
-26
-60
-6
-49
49
89
Interest Expense
2
4
1
0
0
0
0
0
0
0
Depreciation
-
3
3
4
7
19
25
27
23
21
Income Before Tax
-31
-31
-22
-12
-34
-81
-36
-76
25
68
Income Tax Expense
2
5
1
3
0
-6
0
-2
1
1
Net Income
-31
-31
-22
-12
-34
-75
-36
-74
24
66
Net Profit Margin
-48.18%
-43.09%
-25.00%
-10.47%
-29.71%
-34.42%
-12.33%
-20.61%
5.41%
12.83%

Veracyte Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-1
5
15
5
7
0
19
49
28
Operating Cash Flow
-8
29
29
24
5
33
44
52
35
Investing Cash Flow
2
-2
-2
-54
-51
0
48
-5
-127
Financing Cash Flow
0
0
10
-4
-6
0
2
0
-6
Change in Cash
-7
26
38
-34
-52
33
96
47
-99

Veracyte Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-31
-22
-12
-34
-75
-36
-74
24
66
Operating Cash Flow
-23
-13
-3
-9
-31
7
44
75
136
Investing Cash Flow
-1
-1
-42
-3
-739
-29
15
-56
-9
Financing Cash Flow
0
59
127
203
596
3
2
4
-4
Change in Cash
-25
44
81
190
-176
-18
62
23
123

Global Institutional Holdings in Veracyte Common Stock

Funds
Holdings
FMR Inc
9.73%
JPMorgan Chase & Co
1.3%
Wellington Management Company LLP
3.21%
Geode Capital Management, LLC
2.45%
BAMCO Inc
1.11%

Veracyte Common Stock News & Key Events

  • img

    Today's Timeline - 16 February

    Mon, 07:24 PM

    -

    Veracyte to report fourth-quarter 2025 results on Feb. 25, with strong earnings and revenue growth expectations.

    Tue, 06:37 AM

    -

    UBS reaffirms Buy rating on Veracyte, projecting 2026 revenue guidance of $570-$582 million, indicating significant upside potential.

Insights on Veracyte Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, VCYT has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, VCYT stock has moved up by 18.1%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, VCYT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 41.14M → 28.70M (in $), with an average decrease of 30.2% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 140.63M → 139.07M (in $), with an average decrease of 1.1% per quarter

About Veracyte Common Stock

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
OrganisationVeracyte Common Stock
Headquarters6000 Shoreline Court, South San Francisco, CA, United States, 94080
IndustryDiagnostics & Research
CEOMr. Marc A. Stapley
E-voting on sharesClick here to vote

Key Management of Veracyte Common Stock

Name

Title

Mr. Steven French

Senior VP & Chief Information Officer

Mr. Marc A. Stapley

CEO & Director

Ms. Rebecca Chambers

Executive VP & CFO

Ms. Annie McGuire

Executive VP, General Counsel & Head of Market Access

Dr. Keith Gligorich Ph.D.

Senior Vice President of Global Operations

Dr. Kevin Richard Haas Ph.D.

Chief Development and Technology Officer

Dr. Phillip G. Febbo M.D.

Chief Scientific & Medical Officer

Dr. John Leite Ph.D.

Global Chief Commercial Officer

Mr. Jonathan Wygant

VP & Chief Accounting Officer

Ms. Kelly Gura

Director of Investor Relations

FAQs

What is Veracyte Common Stock share price today?

Veracyte Common Stock share price today is $53.19 as on at the close of the market. Veracyte Common Stock share today touched a day high of $54.72 and a low of $52.36.

What is the 52 week high and 52 week low for Veracyte Common Stock share?

Veracyte Common Stock share touched a 52 week high of $54.72 on and a 52 week low of $22.61 on . Veracyte Common Stock stock price today i.e. is closed at $53.19,which is 2.80% down from its 52 week high and 135.25% up from its 52 week low.

What is Veracyte Common Stock's market capitalisation today?

Veracyte Common Stock market capitalisation is $0.00T as on .

How to invest in Veracyte Common Stock Stock (VCYT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Veracyte Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Veracyte Common Stock Shares that will get you 0.0282 shares as per Veracyte Common Stock share price of $53.19 per share as on June 23, 2026 at 8:46 am IST.

What is the minimum amount required to buy Veracyte Common Stock Stock (VCYT) from India?

Indian investors can start investing in Veracyte Common Stock (VCYT) shares with as little as ₹94.68 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.80 in Veracyte Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Veracyte Common Stock share’s latest price of $53.19 as on June 23, 2026 at 8:46 am IST, you will get 0.1880 shares of Veracyte Common Stock. Learn more about fractional shares .

What are the returns that Veracyte Common Stock has given to Indian investors in the last 5 years?

Veracyte Common Stock stock has given 36.11% share price returns and 26.88% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?